Skip to content

NAMS

NewAmsterdam Pharma Co. NV

NASDAQ · Healthcare · Biotechnology · NL

$22.49
+2.55%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 4, 2026
EPS estimate
-$0.50
Revenue estimate
$7.5M

Latest reported

Last report date
Aug 5, 2026
EPS actual
-$0.52
EPS estimate
-$0.48
Revenue actual
$3.7M
Revenue estimate
$2.8M

Track record

Trailing twelve quarters

EPS beats (12Q)
2
EPS misses (12Q)
7
EPS in line (12Q)
0
Avg surprise (4Q)
-15.1%
Revenue beats (12Q)
4

Analyst ratings

Sell-side consensus

Consensus
Buy
Price target
$51
PT range
$50 – $52
Analysts
2
2 Buy0 Hold0 Sell
Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 5, 2026-$0.48-$0.52Miss -7.90%$3.7M
May 7, 2026-$0.46-$0.40Beat 13.04%$3.0M
Feb 18, 2026-$0.40-$0.63Miss -57.50%$32.0K
Nov 5, 2025-$0.38-$0.41Miss -7.89%$348.0K
May 8, 2025-$0.45-$0.49Miss -8.89%$3.2M
Feb 26, 2025-$0.48-$0.95Miss -97.92%$13.2M
Mar 29, 2024-$0.60-$0.57Beat 5.46%$1.8M
Jun 30, 2023-$0.44-$0.52Miss -17.25%$8.6M
Mar 31, 2023-$0.61-$2.37Miss -289.04%$1.5M
Oct 18, 2022-$2.14$5.5M

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026